Literature DB >> 29332937

Improving immune-vascular crosstalk for cancer immunotherapy.

Yuhui Huang1, Betty Y S Kim2, Charles K Chan3, Stephen M Hahn4, Irving L Weissman3, Wen Jiang4.   

Abstract

The vasculature of tumours is highly abnormal and dysfunctional. Consequently, immune effector cells have an impaired ability to penetrate solid tumours and often exhibit compromised functions. Normalization of the tumour vasculature can enhance tissue perfusion and improve immune effector cell infiltration, leading to immunotherapy potentiation. However, recent studies have demonstrated that the stimulation of immune cell functions can also help to normalize tumour vessels. In this Opinion article, we propose that the reciprocal regulation between tumour vascular normalization and immune reprogramming forms a reinforcing loop that reconditions the tumour immune microenvironment to induce durable antitumour immunity. A deeper understanding of these pathways could pave the way for identifying new biomarkers and developing more effective combination treatment strategies for patients with cancer.

Entities:  

Mesh:

Year:  2018        PMID: 29332937      PMCID: PMC5922422          DOI: 10.1038/nri.2017.145

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  129 in total

1.  Multiparametric imaging of tumor response to therapy.

Authors:  Anwar R Padhani; Kenneth A Miles
Journal:  Radiology       Date:  2010-08       Impact factor: 11.105

2.  Is autoimmunity the Achilles' heel of cancer immunotherapy?

Authors:  Carl H June; Jeremy T Warshauer; Jeffrey A Bluestone
Journal:  Nat Med       Date:  2017-05-05       Impact factor: 53.440

Review 3.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.

Authors:  Ivraym B Barsoum; Chelsea A Smallwood; D Robert Siemens; Charles H Graham
Journal:  Cancer Res       Date:  2013-12-13       Impact factor: 12.701

Review 5.  Prospects for combining targeted and conventional cancer therapy with immunotherapy.

Authors:  Philip Gotwals; Scott Cameron; Daniela Cipolletta; Viviana Cremasco; Adam Crystal; Becker Hewes; Britta Mueller; Sonia Quaratino; Catherine Sabatos-Peyton; Lilli Petruzzelli; Jeffrey A Engelman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2017-03-24       Impact factor: 60.716

6.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

7.  Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.

Authors:  V Goede; O Coutelle; J Neuneier; A Reinacher-Schick; R Schnell; T C Koslowsky; M R Weihrauch; B Cremer; H Kashkar; M Odenthal; H G Augustin; W Schmiegel; M Hallek; U T Hacker
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

8.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction.

Authors:  Juliana Hamzah; Manfred Jugold; Fabian Kiessling; Paul Rigby; Mitali Manzur; Hugo H Marti; Tamer Rabie; Sylvia Kaden; Hermann-Josef Gröne; Günter J Hämmerling; Bernd Arnold; Ruth Ganss
Journal:  Nature       Date:  2008-04-16       Impact factor: 49.962

9.  Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo
Journal:  Nat Med       Date:  2016-07-04       Impact factor: 53.440

10.  Current clinical trials testing the combination of immunotherapy with radiotherapy.

Authors:  Josephine Kang; Sandra Demaria; Silvia Formenti
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751

View more
  111 in total

Review 1.  Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.

Authors:  Ning Zhu; Shanshan Weng; Juan Wang; Jiaqi Chen; Linzhen Yu; Xuefeng Fang; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

Review 2.  Focus on Fundamentals: Achieving Effective Nanoparticle Targeting.

Authors:  Gregory T Tietjen; Laura G Bracaglia; W Mark Saltzman; Jordan S Pober
Journal:  Trends Mol Med       Date:  2018-06-05       Impact factor: 11.951

3.  Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma.

Authors:  Laurie Sorenson; Yanfen Fu; Tressa Hood; Sarah Warren; Troy A McEachron
Journal:  Oncoimmunology       Date:  2019-06-27       Impact factor: 8.110

Review 4.  Microenvironmental Metabolism Regulates Antitumor Immunity.

Authors:  Verra M Ngwa; Deanna N Edwards; Mary Philip; Jin Chen
Journal:  Cancer Res       Date:  2019-07-30       Impact factor: 12.701

Review 5.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

Review 6.  Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.

Authors:  Zowi R Huinen; Elisabeth J M Huijbers; Judy R van Beijnum; Patrycja Nowak-Sliwinska; Arjan W Griffioen
Journal:  Nat Rev Clin Oncol       Date:  2021-04-08       Impact factor: 66.675

7.  Combining Nanomedicine and Immunotherapy.

Authors:  Yang Shi; Twan Lammers
Journal:  Acc Chem Res       Date:  2019-05-23       Impact factor: 22.384

Review 8.  The Reciprocity between Radiotherapy and Cancer Immunotherapy.

Authors:  Yifan Wang; Zhi-Gang Liu; Hengfeng Yuan; Weiye Deng; Jing Li; Yuhui Huang; Betty Y S Kim; Michael D Story; Wen Jiang
Journal:  Clin Cancer Res       Date:  2018-11-09       Impact factor: 12.531

Review 9.  Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.

Authors:  John D Martin; Horacio Cabral; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2020-02-07       Impact factor: 66.675

10.  Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice.

Authors:  Simone Ragusa; Borja Prat-Luri; Alejandra González-Loyola; Sina Nassiri; Mario Leonardo Squadrito; Alan Guichard; Sabrina Cavin; Nikolce Gjorevski; David Barras; Giancarlo Marra; Matthias P Lutolf; Jean Perentes; Emily Corse; Roberta Bianchi; Laureline Wetterwald; Jaeryung Kim; Guillermo Oliver; Mauro Delorenzi; Michele De Palma; Tatiana V Petrova
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.